Blog Tag: AngioDynamics

Indiana University Research and Technology Corporation Files Patent Infringement Lawsuit

Indiana University Research and Technology Corporation Files Patent Infringement Lawsuit

Indiana University Research & Technology Corporation (IURTC) filed a lawsuit against AngioDynamics, Inc. alleging infringement of U.S. Patent No. 6,719,717 (“the ‘717 Patent”).  The lawsuit was filed on December 18, 2013 in the Southern District of Indiana.  The ‘717 Patent is entitled “Thrombectomy Treatment System and Method.”

The ‘717 Patent states that it “relates generally to a thrombectomy treatment system and method, and more particularly to a percutaneous thrombectomy system and method providing reinfusion of treated blood that is free of blood clots.”  Figure 1 from the ‘717 Patent is shown below:

The complaint alleges that AngioDynamics infringes the ‘717 Patent by “having made, importing into the United  States, and/or using, selling, and/or offering for sale in the United States,” its AngioVac Cannula and Circuit products.

According to its website, IURTC is a “not-for-profit agency that assists IU faculty and researchers in realizing the commercial potential of their discoveries.”  According to its website, AngioDynamics is headquartered in Albany, New York, and has products that include radiofrequency ablation and NanoKnife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products, venous products and targeted renal therapy products.

AngioDynamics Purchases Ablation Technology

AngioDynamics is going ahead with the purchase of microwave ablation technology from Microsulis Medical, Poststar reports.  According to the story, AngioDynamics plans to incorporate the microwave ablation technology into its own technology “in an all-in-one device that offers a full spectrum of ablation technologies on the same cart, called the ‘total ablation solution.’”  The story summarizes the terms of the deal:

AngioDynamics will pay $10 million cash initially, to be followed by a $5 million cash payment at the end of 2013, according to a statement issued Wednesday. The Latham-based firm will also assume up to $1 million of liabilities on Microsulis’ books.

According to the story, AngioDynamics President and CEO Joseph DeVivo said that he expects the Microsulis technology to improve a thermal ablation business that generated $23 million in 2012.